(NP (-LRB- -LCB-) (JJ Cortisone-resistant) (JJ bronchial) (NN asthma) (-RRB- -RCB-))
(S (S (NP-SBJ (EX There)) (VP (VBZ is) (NP-PRD (NP (JJ general) (NN agreement)) (PP (IN on) (NP (NP (DT the) (JJ inflammatory) (NN pathogenesis)) (PP (IN of) (NP (JJ bronchial) (NN asthma))))))) (: :)) (S (NP-SBJ-COOD-50 (NP (NP (DT an) (NN accumulation)) (PP (IN of) (NP-104 (VBN activated) (NNS eosinophils)))) (, ,) (NP (NP=104 (VBN degranulated) (NN mast) (NNS cells))) (, ,) (NP (NP=104 (NN T) (NNS lymphocytes))) (CC and) (NP (PP (IN in) (NP (ADJP (RB very) (JJ severe)) (NNS forms))) (, ,) (NP=104 (NNS granulocytes)))) (VP (VBZ has) (ADVP-TMP (RB constantly)) (VP (VBN been) (VP (VBN found) (NP (-NONE- *-50)) (PP (IN in) (NP (DT the) (JJ bronchial) (NN mucosa)))))) (. .)))
(S (PP (IN In) (NP (JJ allergic) (JJ bronchial) (NN asthma))) (, ,) (NP-SBJ-51 (NN inflammation)) (VP (VBZ seems) (S (NP-SBJ-52 (-NONE- *-51)) (VP (TO to) (VP (VB be) (VP (VBN orchestrated) (NP (-NONE- *-52)) (PP (ADVP (RB predominantly)) (IN by) (NP-LGS (NP (DT a) (NN subset)) (PP (IN of) (NP (NN T) (NNS lymphocytes))) (, ,) (PP (IN with) (NP (NP (DT a) (NN phenotype)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT the) (NN Th2) (NN subset)) (ADJP (JJ able) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB produce) (NP-COOD (NP (NN IL-4)) (CC and) (NP (NN IL-5))))))))))))))))))) (. .))
(S (SBAR (IN Although) (S (NP-SBJ (NNS corticosteroids)) (VP (VBP are) (NP-PRD (NP (DT the) (ADJP (RBS most) (JJ potent)) (JJ therapeutic) (NNS agents)) (VP (VBN used) (NP (-NONE- *)) (PP (IN for) (NP (DT this) (NN disease)))))))) (, ,) (NP-SBJ (PRP$ their) (JJ anti-inflammatory) (NN effect)) (VP (VBZ differs) (PP-COOD (PP (IN from) (NP (NN patient))) (PP (TO to) (NP (NN patient))))) (. .))
(S (NP-SBJ-53 (NP (DT Some) (NNS criteria)) (SBAR (WHNP-54 (WDT which)) (S (NP-SBJ-55 (-NONE- *T*-54)) (VP (MD can) (VP (VB be) (VP (VBN used) (NP-56 (-NONE- *-55)) (S (NP-SBJ (-NONE- *-56)) (VP (TO to) (VP (VB define) (NP (JJ steroid-resistant) (JJ bronchial) (NN asthma))))))))))) (VP (VBP are) (VP (VBN listed) (NP (-NONE- *-53)) (ADVP (RB here)))) (. .))
(S (NP-SBJ (DT This) (NN review)) (VP (VBZ analyzes) (NP (NP (JJ various) (JJ molecular) (NNS alterations)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ deficient) (NN response)) (PP (TO to) (NP (NN corticosteroid) (NN treatment))) (VP (VBN observed) (NP (-NONE- *)) (PP (IN in) (NP (ADJP (JJ steroid-resistant) (JJ bronchial) (JJ asthmatic)) (NNS subjects))))))))) (. .))
(S (NP-SBJ (NP (JJ New) (NN knowledge)) (PP (IN on) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN steroid) (NN resistance)))))) (VP (MD may) (VP (VB have) (NP (NP (JJ important) (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP-COOD (NP (JJ chronic) (NN asthma)) (CC and) (NP (JJ other) (NNS diseases))))))))) (. .))
